The effectiveness of CureVac's COVID-19 vaccine is among the lowest reported; a new report highlights kickbacks and medical industry payments from device makers to surgeons; Australia limits use of AstraZeneca's COVID-19 vaccine to people over 60 years.
Among the lowest efficacy data reported so far from a COVID-19 vaccine manufacturer, CureVac announced yesterday that its mRNA vaccine candidate is 47% effective against SARS-CoV-2, the virus that causes COVID-19. As reported by The New York Times, trial results were based on data from 135 volunteers who got sick from COVID-19 in Latin America and Europe. More than half of these cases were indicated to have been caused by variants that have been shown to be more transmissible or to lower the effectiveness of vaccines, such as the Lambda variant, prominent in Peru, which accounted for 21% of the samples assessed. The trial is ongoing, with a final analysis expected in 2 to 3 weeks.
A new report from Kaiser Health News (KHN) highlights the issue of kickbacks paid by device makers to orthopedic surgeons to use their products. Notably, medical industry payments to orthopedists and neurosurgeons who operate on the spine were shown to have risen markedly in recent years, with payments ranging from royalties to stock holdings. In fact, a KHN analysis found that compensation flows to these surgeons from manufacturers of hardware for spinal implants, artificial knees, and hip joints totaled more than $3.1 billion from August 2013 to the end of 2019.
Today, Australia’s Minister for Health Greg Hunt said that the country will restrict its recommendation for AstraZeneca's (AZ) COVID-19 vaccine to people older than 60 years, following cases of clotting in people who received the shot. As reported by Reuters, 60 cases of blood clots and 2 resulting deaths have been linked to the 3.3 million doses of the AZ vaccine, which had previously been recommended for those over the age of 50. The move follows similar decision by several European Union member states that have also stopped administering the AZ vaccine in people below a certain age, typically ranging from 50 to 65 years.
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
Navigating Medicare's Part D Subsidy Program to Achieve Value-Based Care
May 26th 2023On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.
Listen
AHN’s Center for Inclusion Health Personalizing Equitable Care Delivery for Marginalized Communities
February 28th 2023On this episode of Managed Care Cast, we speak with Elizabeth Cuevas, MD, division chief of Allegheny Health Network’s (AHN) Center for Inclusion Health, on prevalent health inequities facing marginalized communities and strategies to identify and address these issues.
Listen
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
March 19th 2024The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment pf Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Read More
6 Blood Biomarkers Identified to Predict CVD Risk in Patients With Rheumatoid Arthritis
March 15th 2024Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.
Read More